Oslo Universitetssykehus HF — Sponsor Intelligence | 3 EU Trials

Filter these 3 trials by condition, phase, country and more.

3 Registered trials

0 Recruiting

1 Completed trials

3 Countries active

7 Unique IMPs

100% Results reported

Phase II

Phase IV

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

3 total

High-dose Insulin Euglycemic Therapy in Non-Toxic Acute Cardiogenic Shock. An investigator initiated randomized open labeled pilot trial … Pending

2025-523858-13-01 Phase II 1 country GLUCOSE; INSULIN LISPRO; POTASSIUM CHLORIDE PH. EUR.
The Treat-JIA trial Pending

2026-525611-13-00 Phase IV 1 country ADALIMUMAB; ETANERCEPT; GOLIMUMAB
Safety Trial, DSC vs. BAT in SR acute GvHD Ended

2024-511768-97-01 Phase II 3 countries ALLOGENEIC PLACENTA-DERIVED DECIDUAL STROMAL CELLS, EX-VIVO EXPANDED

Showing 1–3 of 3 trials